세계의 종양 정밀의료 시장 : 유형별, 암 종별, 최종 용도별 예측(2025-2030년)

The Oncology Precision Medicine Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.67 billion in 2024, and is projected to grow at a CAGR of 9.10%, to USD 13.51 billion by 2030.

Oncology precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient's cancer, leveraging genomic, biomarker, and other molecular information to optimize therapeutic efficacy. The necessity of precision medicine arises from its ability to improve treatment outcomes, reduce adverse effects, and enhance the efficiency of healthcare delivery. Its applications span across diagnosis, treatment monitoring, and therapeutic innovation, significantly impacting cancer centers, hospitals, and research institutions. The end-use scope is rapidly expanding to include personalized cancer vaccines, targeted therapies, and next-generation sequencing technologies. Key growth factors influencing the market include technological advancements in genomics, increasing prevalence of cancer, favorable government initiatives, and rising partnerships between pharmaceutical firms and biotech companies. Recent opportunities in this field lie in integrating artificial intelligence and big data analytics to enhance predictive accuracy and developing cost-effective next-generation sequencing methods to widen accessibility. There's also potential in expanding precision medicine applications beyond common cancers into rare and underserved cancer types.

However, challenges such as high costs of advanced diagnostics, complexity in data management, regulatory hurdles, and a need for skilled professionals to interpret complex genetic information pose significant limitations to market growth. Innovation in this sector could focus on developing robust bioinformatics solutions, enhancing the understanding of cancer biology, and creating adaptive clinical trial designs. Furthermore, engaging in collaborations with technology firms could enhance data-driven insights, improving patient stratification and personalized treatment regimens. The market remains highly dynamic, with competition spurring advancements in novel diagnostics and therapeutic methodologies. To capitalize on emerging trends, stakeholders should invest in collaborative research, focus on patient-centric approaches, and actively engage with policymakers to facilitate favorable regulatory frameworks, thus driving broader adoption and integration of precision oncology in routine clinical practice.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Precision Medicine Market

The Oncology Precision Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of cancer among the global population
  • Government initiatives to promote precision medicine
  • Increasing adoption of genetic testing to enhance precision medicine
• Market Restraints
  • Limited reimbursement available for oncology precision medicine treatment
• Market Opportunities
  • Ongoing R&D to develop personalized medicine to treat cancer
  • Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
• Market Challenges
  • Complex regulatory framework surrounding precision oncology

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Precision Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Precision Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Precision Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Precision Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Precision Medicine Market

A detailed market share analysis in the Oncology Precision Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Precision Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Precision Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Precision Medicine Market

A strategic analysis of the Oncology Precision Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, B. J. Madan & Co., Bayer AG, Bristol-Myers Squibb Company, Cepheid Inc., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, Genome Medical boasts, GSK PLC, IQVIA Inc., Laboratory Corporation of America Holding, llumina, Inc., Merck KGaA, Novartis AG, OneOme, LLC, Pfizer Inc., Rain Oncology Inc., Relay Therapeutics, Sanofi S.A., Strata Oncology, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Variantyx, Inc., and Xilis, Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cell & Gene Therapy, Inhibitor drugs, and Monoclonal Antibodies.
• Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
• Based on End-use, market is studied across Hospitals & Diagnostic Laboratories and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of cancer among the global population
    • 5.1.1.2. Government initiatives to promote precision medicine
    • 5.1.1.3. Increasing adoption of genetic testing to enhance precision medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement available for oncology precision medicine treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D to develop personalized medicine to treat cancer
    • 5.1.3.2. Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory framework surrounding precision oncology
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Precision Medicine Market, by Type

• 6.1. Introduction
• 6.2. Cell & Gene Therapy
• 6.3. Inhibitor drugs
• 6.4. Monoclonal Antibodies

7. Oncology Precision Medicine Market, by Cancer Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cervical Cancer
• 7.4. Colorectal Cancer
• 7.5. Lung Cancer
• 7.6. Prostate Cancer

8. Oncology Precision Medicine Market, by End-use

• 8.1. Introduction
• 8.2. Hospitals & Diagnostic Laboratories
• 8.3. Pharmaceutical & Biotechnology Companies

9. Americas Oncology Precision Medicine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncology Precision Medicine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Precision Medicine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca PLC
• 3. B. J. Madan & Co.
• 4. Bayer AG
• 5. Bristol-Myers Squibb Company
• 6. Cepheid Inc.
• 7. Eli Lilly & Company
• 8. F. Hoffmann-La Roche Ltd
• 9. Genome Medical boasts
• 10. GSK PLC
• 11. IQVIA Inc.
• 12. Laboratory Corporation of America Holding
• 13. llumina, Inc.
• 14. Merck KGaA
• 15. Novartis AG
• 16. OneOme, LLC
• 17. Pfizer Inc.
• 18. Rain Oncology Inc.
• 19. Relay Therapeutics
• 20. Sanofi S.A.
• 21. Strata Oncology, Inc.
• 22. Takeda Pharmaceutical Company Limited
• 23. Thermo Fisher Scientific, Inc.
• 24. Variantyx, Inc.
• 25. Xilis, Inc.